In some countries, in particular in the United States, applicable laws may restrict or prohibit a public distribution of information contained on the following websites. Therefore, please provide the following information:
You have indicated that you are located in the United States. These materials are not intended for, directed at or accessible by persons located in the United States. However, persons located in the United States that are able to make the certifications below may access these materials. Please read the certifications below carefully and tick the checkboxes if you can make the certifi-cations. If you cannot make the certifications below, please choose “I DO NOT AGREE” below.
The information contained on the following web pages is intended exclusively for Swiss resi-dents who are physically located in Switzerland or persons who have identified themselves as “qualified institutional buyers” as defined in, and in reliance on, Rule 144A under the U.S. Securities Act of 1933, as amended (the “Securities Act”). The following information does not contain or constitute an offer to sell or a solicitation of any offer to buy securities in the United States of America (the "United States") or in any other jurisdiction in which such offer or solicitation is not authorized or to any person to whom it is unlawful to make an offer or solicitation. Users of this web site are requested to inform themselves about and to observe any such restrictions. The se-curities of Santhera Pharmaceuticals Holding AG have not been and will not be registered under the United States securities laws and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act. Santhera Pharmaceuticals Holding AG does not intend to register any portion of the offering in the United States or conduct a public offering of securities in the United States. The information contained on the following web pages may not be distributed outside of Switzerland, in particular not in the United States.
This communication is only being distributed to and is only directed at persons who are outside the United Kingdom ("U.K.") (all such persons together being referred to as "Relevant Persons"). Any person who is not a Relevant Person should not act or rely on the following web pages or any of their contents. Santhera Pharmaceuticals Holding AG's securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securi-ties will be engaged in only with, relevant persons and certain other persons to whom it may law-fully be communicated.
Some of the information published on this website contains forward-looking statements. Users are cautioned that any such forward-looking statements are not guarantees of future perfor-mance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Santhera Pharmaceuticals Holding AG undertakes no obligation to publicly update or revise any information or opinions published on the website. Santhera Pharmaceuticals Holding AG reserves the right to amend the information at any time without prior notice.
The information contained on this website may not be considered as being a substitute for eco-nomic, legal, tax or other advice and users are cautioned to base investment decisions or other decisions solely on the content of this website. The securities of Santhera Pharmaceuticals Holding AG described in the information on this website are not being offered publicly inside or out-side of Switzerland. In any case, an investment decision with respect to publicly traded securities of Santhera Pharmaceuticals Holding AG must only be made on the basis of the listing prospectus published in accordance with Swiss stock exchange rules. Users must consult their investment advisers or other advisers prior to making any decisions.
Please confirm that you have read the complete legend and accept its terms:
You did not identify yourself with a valid address in Switzerland or you are unable to identify yourself as a “qualified institutional buyer” as defined in, and in reliance on, Rule 144A under the U.S. Securities Act of 1933, as amended (the “Securities Act”). We therefore regret that we can-not provide you with the desired information. The information set forth on this website must not be distributed outside of Switzerland, in particular not in the United States of America. Each vio-lation of such limitations may constitute a violation of the applicable securities laws of such countries, particularly in the United States. In other countries, the public dissemination of the information contained on these internet pages is prohibited or restricted by law. Shares of Santhera Pharmaceuticals Holding AG described in the information on this website are not being offered publicly inside or outside of Switzerland.
For legal reasons, the following information is intended exclusively for Swiss residents who are physically located in Switzerland or persons who have identified themselves as “qualified institutional buyers” as defined in, and in reliance on, Rule 144A under the U.S. Securities Act of 1933, as amended (the “Securities Act”).
Santhera Raises Gross Proceeds of CHF 23.5 Million and Secures Acquisition of Option to Vamorolone Sub-license - December 14, 2018
Santhera Provides Update on the Share Placement - December 14, 2018
Offering And Listing Memorandum - December 12, 2018
Santhera Launches Placement of Shares through Accelerated Bookbuilding - December 12, 2018
Audio-Webcast of November 21, 2018 - link to replay
Presentation on vamorolone and the agreement between Santhera and Idorsia - Thomas Meier, CEO - November 21, 2018
Santhera Enters into Agreement to Acquire Option from Idorsia for Exclusive Sub-License of First-in-class Dissociative Steroid Vamorolone - November 20, 2018
Santhera Calls Extraordinary General Meeting and Proposes Ordinary Share Capital Increase to Raise Approximately CHF 50 Million - November 20, 2018